1 Correction to: Pediatr Drugs 2018 20(1):97–104 https://doi.org/10.1007/s40272-017-0264-y
Page 98, Section 2.1: The following sentence, which previously read:
“Newborns, infants, or young children aged 24 months and under who have Down syndrome, and children ≤ 24 months of age without a current hs-CHD if they had experienced persistent respiratory symptoms or regular outpatient treatment due to a respiratory tract infection in previous RSV seasons were also eligible for the study.”
Should read:
“Newborns, infants, or young children aged 24 months and under who have Down syndrome (without a current hs-CHD) were also eligible for the study.”
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kashiwagi, T., Okada, Y. & Nomoto, K. Correction to: Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan. Pediatr Drugs 20, 291 (2018). https://doi.org/10.1007/s40272-018-0291-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40272-018-0291-3